Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
43.52 USD | +1.00% |
|
+7.51% | -27.67% |
06-17 | Truist Securities Initiates Legend Biotech With Buy Rating, $88 Price Target | MT |
06-03 | Legend Biotech Says Phase 2 Trial of Carvykti to Treat Multiple Myeloma Showed 'Deep, Durable' Responses | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-27.67% | 7.93B | |
+16.45% | 122B | |
+21.96% | 116B | |
+24.60% | 27.03B | |
-20.05% | 20.36B | |
-16.57% | 16.43B | |
-16.28% | 15.91B | |
-44.35% | 15.6B | |
+63.91% | 14.94B | |
+2.52% | 13.59B |
- Stock Market
- Equities
- LEGN Stock
- News Legend Biotech Corporation
- Legend Expects to Log Profit in 2026